Lupin
Ticker > Company >

Lupin share price

Lupin Ltd.

NSE: LUPIN BSE: 500257 SECTOR: Pharmaceuticals & Drugs  3.11 L   881   153

1898.90
+5.80 (0.31%)
BSE: 29 Aug 04:01 PM

Price Summary

Today's High

₹ 1912.35

Today's Low

₹ 1889.3

52 Week High

₹ 2403.45

52 Week Low

₹ 1774

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 86733.12 Cr.

Enterprise Value

₹ 86274.54 Cr.

No. of Shares

45.68 Cr.

P/E

16.64

P/B

3.29

Face Value

₹ 2

Div. Yield

0.63 %

Book Value (TTM)

₹  576.33

CASH

₹ 458.58 Cr.

DEBT

₹ 0 Cr.

Promoter Holding

46.9 %

EPS (TTM)

₹  114.11

Sales Growth

15.69%

ROE

17.78 %

ROCE

21.92%

Profit Growth

70.8 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Lupin Ltd.

Molnulup Respira endeavour maxter pinnacle blue eyes femina midvision CVN ONDERO Piclin Menoctyl Sucramal O Pyridium Distaclor Vilfuro-G

Index Presence

The company is present in 44Indices.

NFT150MOM50

Nifty Midcap150 Momentum 50
59410.45
  -358.350000000006 (-0.599560305711355%)

NIFTYMIDCAP

NIFTY Midcap 100
55727.4
  -320.099999999999 (-0.57112270841696%)

NIFTYALPHA

Nifty Alpha 50
49066.25
  -394.650000000001 (-0.797902990038601%)

NYMIDSML400MQ100

Nifty MidSmallcap400 Momentum Quality 100 Index
46704
  -130.050000000003 (-0.277682583504957%)

NFTALLO30

NIFTY Alpha Low-Volatility 30
26119.4
  13.8000000000029 (0.0528622211326324%)

NIFTYLOWVOL

Nifty Low Volatility 50
24793
  14.6500000000015 (0.059124195113891%)

NT200ALP30

NIFTY200 Alpha 30
24381.25
  -142.700000000001 (-0.581880162045678%)

NIFTY500

Nifty 500
22462.95
  -78.7000000000007 (-0.349131496585209%)

NIFTYPHARMA

Nifty Pharma
21804.05
  -4.29999999999927 (-0.0197172184048688%)

NIFTYMIDCAP150

Nifty Midcap 150
20750.3
  -114.450000000001 (-0.548532812518721%)

NIFTYMIDSMALL400

Nifty MidSmallcap 400
19232.3
  -90.6000000000022 (-0.468873719783269%)

NIF500LGMIDSML

Nifty500 LargeMidSmall Equal-Cap Weighted Index
17214.65
  -67.5999999999985 (-0.391152772353132%)

NIFTYLGEMID250

NIFTY LargeMidcap 250
15745.15
  -67.1000000000004 (-0.424354535249571%)

MIDCAP50

Nifty Midcap 50
15714.75
  -102.6 (-0.648654799950688%)

NY500MUL50:25:25

Nifty500 Multicap 50:25:25
15627.45
  -57.75 (-0.368181470430728%)

NY500MUL50:30:20

Nifty500 Multicap India Manufacturing 50:30:20
14882.5
  -75.7999999999993 (-0.506742076305455%)

LIX 15 MIDCAP

Nifty Midcap Liquid 15
14664.75
  -145 (-0.979084724590218%)

NIFTYHEALTH

Nifty Healthcare Index
14350.3
  -25.3000000000011 (-0.175992654219659%)

NIFTYMFG

Nifty Manufacturing
14236.85
  -35.3500000000004 (-0.247684309356655%)

NFT500EQUAL

Nifty 500 Equal Weight
13873.45
  -51.5999999999985 (-0.370555222422886%)

NIFTY200

Nifty 200
13575.1
  -47.1499999999996 (-0.346124905944312%)

NIFTYTOTALMCAP

Nifty Total Market index
12641.45
  -43.3999999999996 (-0.342140427360194%)

NIFTYMIDSELECT

Nifty Midcap Select
12450.2
  -84.9499999999989 (-0.677694323562139%)

SNXT50

S&P Bse Sensex Next 50
81474.64
  -204.309999999998 (-0.250137887423874%)

MIDCAP

S&P Bse Mid Cap
44642.31
  -183.93 (-0.410317706771746%)

BSE HC

S&P Bse Healthcare
43622.7
  -71.3500000000058 (-0.163294544680581%)

BSE500

S&P Bse 500
35287.71
  -122.010000000002 (-0.344566407189895%)

BSE100

S&P Bse 100
25556.76
  -81.4200000000019 (-0.317573244278657%)

FOCMID

BSE Focused Midcap
22983.93
  -20.8400000000001 (-0.0905899080929751%)

BSEIND150

BSE India 150 Index
18193.47
  -60.0099999999984 (-0.328759228377262%)

MIDSEL

S&P Bse MidCap Select Index
16164.27
  -36.4899999999998 (-0.225236346936808%)

MID150

S&P Bse 150 MidCap
15525.18
  -69.8999999999996 (-0.448218284228097%)

200EQW

BSE 200 Equal Weight
12581.77
  -48.0499999999993 (-0.380448810830236%)

S&P MIDSMLCAP

S&P Bse MidSmallCap
12414.1
  73.2299999999996 (0.593394144821224%)

MSL400

S&P Bse 400 MidSmallCap
11668.55
  -44.3400000000001 (-0.378557298839144%)

BSE200

S&P Bse 200
11048.51
  -39.119999999999 (-0.352825626396258%)

BSE1000

Bse 1000
10511.3
  -35.3400000000001 (-0.335083021701699%)

LMI250

S&P Bse 250 LargeMidCap
10493.85
  -37.3799999999992 (-0.354944294256221%)

S&P LARGEMIDCAP

S&P Bse Large MidCap
10319.66
  72.75 (0.709970127579918%)

ALLCAP

S&P Bse Allcap
10130.99
  38.3799999999992 (0.380278243189802%)

SHA500

S&P Bse 500 Shariah
9113.66
  125.5 (1.39628133010539%)

CARBONEX

S&P Bse Carbonex
4344.48
  15.7799999999997 (0.364543627417002%)

SPBSMOIP

S&P Bse Momentum
2162.69
  -7.03999999999996 (-0.324464334272001%)

ESG100

S&P Bse 100 ESG Index
408.29
  -1.31 (-0.319824218749998%)

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year15.69%
3 Year12.96%
5 Year9%

Profit Growth

1 Year70.8%
3 Year184.61%
5 Year40.43%

ROE%

1 Year17.78%
3 Year10.71%
5 Year7.63%

ROCE %

1 Year21.92%
3 Year13.18%
5 Year9.66%

Debt/Equity

0

Price to Cash Flow

35.48

Interest Cover Ratio

58.244

CFO/PAT (5 Yr. Avg.)

1.08592308620022

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 46.90 0.00
Mar 2025 46.92 0.00
Dec 2024 46.95 0.00
Sep 2024 46.96 0.00
Jun 2024 46.98 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 184.610618425016% for the Past 3 years.
  • The company has significantly decreased its debt by 18.13 Cr.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 58.244.
  • Company’s PEG ratio is 0.2361731323464.
  • The company has an efficient Cash Conversion Cycle of -10.9677 days.
  • Company has a healthy liquidity position with current ratio of 3.6138.
  • The company has a good cash flow management; CFO/PAT stands at 1.08592308620022.

 Limitations

  • The company has shown a poor revenue growth of 12.9603589470559% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 4167.63 4106.2 4208 4485.67 5708.59
Total Expenditure 2967.96 2991.45 2796.95 2739.54 2978.95
Operating Profit 1199.67 1114.75 1411.05 1746.13 2729.64
Other Income 38.22 32.62 55.3 48.79 54.14
Interest 13.55 17.55 19.55 33.85 18.9
Depreciation 141.42 145.77 152.52 207.98 176.73
Exceptional Items 0 0 -77.22 0 0
Profit Before Tax 1082.92 984.05 1217.06 1553.09 2588.15
Tax 193.74 176.29 232.39 261.74 460.08
Profit After Tax 889.18 807.76 984.67 1291.35 2128.07
Adjusted EPS (Rs) 19.5 17.71 21.58 28.28 46.59

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 11055.93 11771.67 11258.83 14666.5 16967.5
Total Expenditure 9011.87 11566.69 10294.93 11227.12 11574.36
Operating Profit 2044.06 204.98 963.9 3439.38 5393.14
Other Income 129.09 221.15 210.02 126.41 253.39
Interest 40.62 73.47 98.44 56.35 84.5
Depreciation 502.83 514.19 548.34 724.75 647.69
Exceptional Items 0 0 0 0 -77.22
Profit Before Tax 1629.7 -161.53 527.14 2784.69 4837.12
Tax 371.08 27.17 101.93 458.6 864.16
Net Profit 1258.62 -188.7 425.21 2326.09 3972.96
Adjusted EPS (Rs.) 27.74 -4.15 9.35 51.04 87.01

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 90.74 90.9 91 91.14 91.32
Total Reserves 18474.83 18059.29 18320.86 20511.95 24186.92
Borrowings 0.15 0 0 0 0
Other N/C liabilities 707.01 625.27 643.96 625.83 854
Current liabilities 2585.83 3537.91 3627.85 3646.42 3232.52
Total Liabilities 21858.56 22313.37 22683.67 24922.86 28431.98
Assets
Net Block 3638.83 3690.18 4021.93 4113.17 4945.86
Capital WIP 795.83 773.74 737.99 411.12 231.9
Intangible WIP 155.03 173.7 188.6 34.71 46.47
Investments 7241.59 8688.69 9534.56 10771.82 10951.47
Loans & Advances 399.62 537.04 603.86 259.03 347.62
Other N/C Assets 10.29 12.2 25.81 192.83 227.13
Current Assets 9617.37 8437.82 7570.92 9140.18 11681.53
Total Assets 21858.56 22313.37 22683.67 24922.86 28431.98
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 1629.7 -161.53 527.14 2784.69 4837.12
Adjustment 487.06 449.36 583.79 771.3 712.12
Changes in Assets & Liabilities -118.04 -284.97 809.86 -905.21 -2296.4
Tax Paid -428.64 148.17 -126.8 -146.65 -808.19
Operating Cash Flow 1570.08 151.03 1793.99 2504.13 2444.65
Investing Cash Flow -2507.52 -371.79 -1269.17 -1599.02 -1766.32
Financing Cash Flow -53.17 102.45 -498.26 -867.07 -460.23
Net Cash Flow -990.61 -118.31 26.56 38.04 218.1

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 46.98 46.96 46.95 46.92 46.90
anuja gupta 0.16 0.16 0.16 0.16 0.16
d b gupta - - - - 0.14
kavita gupta 0.04 0.04 0.04 0.04 0.04
lupin investments private... - - - - 45.37
manju d gupta 0.85 0.85 0.85 0.85 0.85
neel deshbandhu gupta 0.01 0.01 0.01 0.01 0.01
nilesh gupta - - - - 0.20
richa gupta 0.05 0.05 0.05 0.05 0.05
veda nilesh gupta 0.02 0.02 0.02 0.02 0.02
vinita gupta 0.07 0.07 0.07 0.07 0.07
desh bandhu gupta huf 0.14 0.14 0.14 0.14 -
lupin investments pvt ltd... 45.45 45.42 45.41 45.38 -
nilesh d gupta 0.20 0.20 0.20 0.20 -
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 53.02 53.04 53.05 53.08 53.10
axis mutual fund trustee ... - 1.30 1.38 1.54 1.29
hdfc life insurance compa... 1.33 1.38 1.32 1.31 1.31
hdfc trustee company ltd.... - - - - 3.78
icici prudential value di... 3.46 2.54 2.61 2.63 3.22
investor education and pr... - 0.16 0.17 - 0.17
llp 0.12 0.05 0.03 0.03 0.01
mirae asset large & midca... - - - - 1.52
nippon life india trustee... - - - - 2.10
nps trust- a/c hdfc pensi... - - 1.31 - 1.48
sbi long term equity fund... 1.17 1.60 1.63 1.62 1.72
hdfc trustee company ltd-... 3.60 3.37 3.36 3.22 -
investor education and pr... 0.17 - - 0.17 -
life insurance corporatio... 5.13 2.89 2.27 2.05 -
mirae asset large and mid... 1.53 1.02 1.20 1.42 -
nippon life india trustee... 1.86 1.81 1.90 1.88 -
nps trust-a/c hdfc pensio... - - - 1.42 -
sbi life insurance co. lt... - - - 1.07 -
sbi life insurance compan... - 1.04 1.05 - -

Annual Reports

Title Link
Title Link
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit ICRA
Credit ICRA
Credit ICRA
TYPE AGENCY Link
TYPE AGENCY Link
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research Geojit
Research Report By:
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research HDFC Securities
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research Motilal Oswal
Research Prabhudas Lilladhar
Research ICICI Securities Limited
Research Nirmal Bang Institutional
Research HDFC Securities
Research BOB Capital Markets Ltd.

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY24
Concall Q4FY22
Concall Q4FY21
Concall Q3FY25
Concall Q3FY24
Concall Q3FY23
Concall Q3FY22
Concall Q3FY21
Concall Q3 FY20
Concall Q2FY24
Concall Q2FY23
Concall Q2FY22
Concall Q1FY26
Concall Q1FY25
Concall Q1FY24
Concall Q1FY22
Concall Q1FY21
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY25
Presentation Q4FY24
Presentation Q4FY21
Presentation Q3FY24
Presentation Q3FY23
Presentation Q3FY22
Presentation Q2FY24
Presentation Q2FY22
Presentation Q2FY21
Presentation Q1FY25
Presentation Q1FY24
Presentation Q1FY22
Presentation Q1FY21

Additional Resources & References

Company News

Lupin informs about updates 29 Aug, 3:42 PM Lupin informs about press release 20 Aug, 11:36 AM Lupin launches Bosentan Tablets for Oral Suspension in United States 20 Aug, 11:00 AM Lupin partners with Sandoz Group AG 12 Aug, 2:40 PM Lupin launches Glucagon for Injection USP, 1mg/vial in United States 11 Aug, 11:50 AM Lupin reports 52% rise in Q1 consolidated net profit 6 Aug, 12:16 PM Lupin informs about investor presentation 6 Aug, 11:59 AM Lupin - Quaterly Results 5 Aug, 8:40 PM Lupin - Quaterly Results 5 Aug, 8:40 PM Lupin gets USFDA’s nod for Liraglutide and Glucagon Injectable Products 24 Jul, 2:30 PM Lupin informs about press release 24 Jul, 1:10 PM USFDA concludes inspection at Lupin’s Pithampur Unit-2 manufacturing facility 18 Jul, 12:59 PM Lupin’s arm receives GMP certification from Therapeutic Goods Administration 18 Jul, 11:19 AM USFDA concludes inspection at Lupin’s Pithampur unit 3 manufacturing facility 18 Jul, 10:22 AM Lupin launches Loteprednol Etabonate Ophthalmic Suspension in United States 16 Jul, 6:34 PM Lupin informs about press release 16 Jul, 4:48 PM Lupin informs about ESG rating 10 Jul, 5:21 PM Lupin signs license and supply agreement with Zentiva 9 Jul, 11:11 AM Lupin launches Ipratropium Bromide Nasal Solution in United States 4 Jul, 5:43 PM Lupin gets USFDA’s nod for Loteprednol Etabonate Ophthalmic Gel 2 Jul, 9:07 AM Lupin executes BTA for transfer of API R&D Division to Lupin Manufacturing Solutions 1 Jul, 11:53 AM Lupin executes BTA for transfer of OTC Business to LUPINLIFE Consumer Healthcare 1 Jul, 10:23 AM Lupin launches Prucalopride Tablets in United States 26 Jun, 4:30 PM Lupin gets USFDA’s nod for Prucalopride Tablets 25 Jun, 2:30 PM Lupin informs about analyst meet 19 Jun, 5:17 PM Lupin informs about press release 16 Jun, 2:44 PM Lupin informs about press release 16 Jun, 1:57 PM Lupin signs license and supply agreement with Sino Universal Pharmaceuticals 16 Jun, 11:10 AM Lupin gets USFDA’s approval for Oxcarbazepine ER tablets 9 Jun, 10:09 AM Lupin informs about press release 26 May, 2:12 PM Lupin enters into license, supply agreement with SteinCares 26 May, 11:49 AM Lupin informs about press release 20 May, 4:59 PM Lupin, Honeywell move forward jointly with plans for HFO Technology in Inhalers 20 May, 2:51 PM Lupin gets USFDA’s nod for Rivaroxaban Tablets 15 May, 4:30 PM Lupin reports over two-fold jump in Q4 consolidated net profit 15 May, 12:00 PM Lupin - Quaterly Results 14 May, 10:24 PM Lupin - Quaterly Results 14 May, 10:24 PM Lupin launches Tolvaptan Tablets in United States 13 May, 2:44 PM Lupin informs about press release 13 May, 12:12 PM Lupin launches Eslicarbazepine Acetate Tablets 8 May, 9:28 AM Lupin informs about analyst meet 2 May, 5:24 PM Lupin informs about press release 24 Apr, 12:11 PM Lupin gets USFDA’s nod for Tolvaptan Tablets 24 Apr, 12:00 PM Lupin’s arm recalling 2,724 bottles of Clomipramine hydrochloride Capsules 23 Apr, 4:00 PM Lupin’s arm achieves NABL accreditation across all greenfield labs 23 Apr, 2:30 PM Lupin informs about press release 23 Apr, 12:12 PM Lupin gets EIR from USFDA for injectable facility in Nagpur 17 Apr, 4:09 PM Lupin informs about certificate 7 Apr, 2:09 PM Lupin’s arm acquires Renascience Pharma in United Kingdom 3 Apr, 9:19 AM Lupin’s arm launches post-procedure home-based care guide with ACC 24 Mar, 12:30 PM

Lupin Stock Price Analysis and Quick Research Report. Is Lupin an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Lupin. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Lupin has a PE ratio of 16.6064595964111 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Lupin has ROA of 14.8926% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Lupin has a Current ratio of 3.6138.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Lupin has a ROE of 17.7816%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Lupin has a Debt to Equity ratio of 0 which means that the company has low proportion of debt in its capital.

  • Sales growth: Lupin has reported revenue growth of 15.6888% which is fair in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Lupin for the current financial year is 31.7851186091056%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Lupin is Rs 12 and the yield is 0.6339%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Lupin is Rs 114.1062. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Lupin in Ticker for free. Also, one can get the intrinsic value of Lupin by using Valuation Calculators, which are available with a Finology ONE subscription. 

Lupin FAQs

Q1. What is Lupin share price today?
Ans: The current share price of Lupin is Rs 1894.9.

Q2. What is the market capitalisation of Lupin?
Ans: Lupin has a market capitalisation of Rs 86550.41342633 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Lupin?
Ans: The PE ratio of Lupin is 16.6064595964111 and the P/B ratio of Lupin is 3.28784588402436, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Lupin share?
Ans: The 52-week high share price of Lupin is Rs 2402.9, and the 52-week low share price of Lupin is Rs 1795.2.

Q5. Does Lupin pay dividends?
Ans: Currently, Lupin pays dividends. Dividend yield of Lupin is around 0.6339%.

Q6. What are the face value and book value of Lupin shares?
Ans: The face value of Lupin shares is Rs 2, while the book value per share of Lupin is around Rs 576.3348. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Lupin?
Ans: Lupin has a total debt of Rs 0 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Lupin?
Ans: The ROE of Lupin is 17.7816% and ROCE of Lupin is 21.9228%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Lupin a good buy for the long term?
Ans: The Lupin long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Lupin undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Lupin appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Lupin’s financials?
Ans: You can review Lupin’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Lupin

Lupin Ltd. Financials: Check Share Price, Balance Sheet, Annual Report and Quarterly Results for Company Analysis

Welcome to our Lupin Ltd. stock analysis page, where long-term investors can find a wealth of information and resources to make informed decisions about their investment positions. We provide a comprehensive analysis of various aspects of Lupin Ltd.'s stock performance, allowing investors to gain valuable insights into the company's financial stability, growth prospects, and long-term viability. Let us delve into each topic in detail.

Lupin Ltd. Share Price Analysis

Analyzing the share price of Lupin Ltd. is crucial for long-term investors to understand the company's growth potential and market sentiment. Our pre-built screening tools enable investors to track the historical share price of Lupin Ltd. over different timeframes. By studying price trends, trading volumes, trading range, and the stock's relative performance compared to market indices, investors gain insights into Lupin Ltd.'s financial stability, growth prospects, and investment viability. In addition to these screening tools, our platform provides premium features tools such as DCF Analysis, BVPS Analysis, Earnings multiple approaches, and DuPont analysis, which offer a more comprehensive analysis of Lupin Ltd.'s intrinsic value and growth potential.

Lupin Ltd. Balance Sheet Evaluation

Evaluating Lupin Ltd.'s balance sheet is a critical step for long-term investors to understand the company's financial position and growth potential. Our pre-built screening tools enable investors to determine Lupin Ltd.'s balance sheet ratios and metrics. By examining key financial indicators such as current assets, current liabilities, and long-term debt, investors gain insights into Lupin Ltd.'s financial stability, liquidity, and potential for growth. Additionally, our platform provides premium features tools such as DCF Analysis, BVPS Analysis, Earnings multiple approaches, and DuPont analysis, which provide a more comprehensive analysis of Lupin Ltd.'s balance sheet, helping investors assess its long-term investment potential.

Lupin Ltd. Annual Report Insights

Lupin Ltd.'s annual reports offer a wealth of information about the company's performance, strategies, and plans. On our platform, you can access downloadable PDF versions of Lupin Ltd.'s annual reports, along with expert reviews and analysis. These annual reports provide insights into Lupin Ltd.'s business model, competitive landscape, and macroeconomic factors that may impact its operations. Coupled with our premium features tools, investors can conduct a thorough analysis and make well-informed decisions based on Lupin Ltd.'s annual reports.

Lupin Ltd. Dividend Payments

Analysing Lupin Ltd.'s dividend payments is crucial for long-term investors seeking stable returns. Our stock analysis page provides comprehensive data on the company's dividend payment history. By analysing Lupin Ltd.'s profitability, dividend policy, and metrics such as the dividend yield and payout ratio, investors can make well-informed decisions about their long-term investment positions. Alongside our dividend payment information, our platform offers premium features tools such as DCF Analysis, BVPS Analysis, Earnings multiple approaches, and DuPont analysis, which allow investors to evaluate the impact of dividends on Lupin Ltd.'s stock value and overall investment strategy.

Lupin Ltd. Quarterly Results Analysis

Analyzing Lupin Ltd.'s quarterly results helps investors evaluate its short-term performance and gauge its future growth potential. On our platform, you can find downloadable PDF files of Lupin Ltd.'s quarterly results, enabling investors to assess the company's recent performance and key financial metrics such as revenue growth, earnings per share, and margins. By leveraging our premium features tools and conducting a thorough analysis, long-term investors can make well-informed decisions regarding their investment positions in Lupin Ltd.

Lupin Ltd. Stock Price Trends

Analyzing Lupin Ltd.'s stock price trends is essential for understanding its growth potential and market sentiment. Our pre-built screening tools enable investors to track Lupin Ltd.'s stock price trends over different timeframes. This allows the identification of short-term and long-term patterns and pricing volatility. By utilizing our premium features tools, investors gain additional insights into factors affecting Lupin Ltd.'s stock performance, aiding them in making well-informed decisions.

Lupin Ltd. Price Charts

Technical analysis through price chart analysis provides additional insights into Lupin Ltd.'s stock performance. On our website, you can access dynamic price charts that display historical price movements, technical indicators, and patterns. These charts assist investors in identifying potential entry and exit points, support and resistance levels, and trend reversals. By incorporating these insights into our premium features tools, investors can conduct a comprehensive analysis and make informed decisions about Lupin Ltd. as a long-term investment.

Lupin Ltd. News Updates

Keeping up with the latest news and developments concerning Lupin Ltd. is fundamental for long-term investors. Our website provides comprehensive and timely information sourced from reliable news channels. Through articles and news updates, investors gain insights into Lupin Ltd.'s industry trends, market position, and future outlook. This information empowers investors to make well-informed decisions and stay ahead of market dynamics affecting their long-term investment positions.

Lupin Ltd. Conference Calls

Lupin Ltd.'s conference calls offer crucial insights into the company's operations, financial performance, and growth strategies. On our platform, you can find a searchable collection of Lupin Ltd.'s conference calls, including downloadable recordings. By listening to these calls, investors gain a deep understanding of Lupin Ltd.'s management team, growth plans, and economic factors impacting the company's performance. Leveraging our premium features tools, investors can carry out comprehensive analyses and make well-informed decisions regarding their long-term investment positions in Lupin Ltd.

Lupin Ltd. Transcripts

Transcripts of Lupin Ltd.'s conference calls capture important discussions and insights. Our platform provides downloadable transcripts that include in-depth analyses of the company's financial performance, future plans, and market trends. Reviewing these transcripts offers valuable insights into Lupin Ltd.'s strategies, growth potential, and adaptability to market dynamics. By leveraging our premium features tools and conducting a comprehensive analysis, investors can make well-informed decisions about Lupin Ltd. as a long-term investment.

Lupin Ltd. Investor Presentations

Lupin Ltd.'s investor presentations offer detailed information about the company's financials, strategic initiatives, and future plans. On our platform, you can easily access these investor presentations in downloadable PDF format. These presentations provide insights beyond the numbers, delving deep into Lupin Ltd.'s growth strategy, market expansion plans, and competitive advantages. By leveraging our premium features tools and conducting thorough analyses, investors can make sound investment decisions based on Lupin Ltd.'s investor presentations.

Lupin Ltd. Promoters and Shareholders

Understanding the ownership structure of Lupin Ltd. is crucial for long-term investors evaluating the company's growth potential and stability. Our pre-built screening tools enable investors to assess promoter holdings and analyze the company's shareholder base. By understanding the distribution of ownership and the alignment of interests, investors can make well-informed decisions about their long-term investment positions in Lupin Ltd.

Lupin Ltd. ROCE

Return on Capital Employed (ROCE) is a key financial metric that indicates the efficiency and profitability of a company's capital investments. It is a crucial factor in evaluating Lupin Ltd.'s financial performance. You can conveniently access ROCE data for Lupin Ltd. in the financials table or ratio section on this page.

Lupin Ltd. EBITDA

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) provides insight into Lupin Ltd.'s operating profitability. This metric is essential for assessing the company's financial health. Detailed EBITDA data for Lupin Ltd. can be found in the financials table or ratio section located on this page.

Lupin Ltd. DPS

Dividends Per Share (DPS) is a vital indicator for investors seeking information about the dividend distribution of Lupin Ltd. This page offers access to DPS data as it pertains to the company, which aids in evaluating its dividend policy and performance.

Lupin Ltd. EPS

Earnings Per Share (EPS) is a fundamental metric for analyzing Lupin Ltd.'s profitability and investment potential. This information is readily available on this page in the financials table or ratio section. EPS data allows for a comprehensive assessment of the company’s earnings and financial outlook.

Read More
X